Predictors of Virologic Response to Lamivudine Treatment in Children with Chronic Hepatitis B Infection

Pediatric Infectious Disease Journal

Volumn 23, Issue 5, 2004, Pages 441-445

  Hom, Xenia ^b   Little, Nancy R ^c   Gardner, Stephen D ^c   Jonas, Maureen M ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Children; Hepatitis B; Lamivudine; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; ETHNIC DIFFERENCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER DISEASE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEROCONVERSION;

ADOLESCENT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; DOUBLE-BLIND METHOD; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 2442561268     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000126412.93562.f5     Document Type: Article

References (13)

1. Yuen M-F, Hui C-K, Cheng C-C, Wu C-H, Lai Y-P, Lai C-L. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology. 2001;34:139-145.
2. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003;37:748-755.
3. Torre D, Tambini R. Interferon-α therapy for chronic hepatitis B in children: a meta-analysis. Clin Infect Dis. 1996;23:131-137.
4. Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology. 1998;114:988-995.
5. Jonas MM, Kelly DA, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002;346:1706-1713.
6. Perrillo RP, Lai CL, Liaw Y-F, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002;36:186-194.
7. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest. 1998;102: 968-975.
8. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to α interferon therapy? A statistical analysis of predictive factors. Hepatology. 1989;10:761-763.
9. Lok AS. α-Interferon therapy for chronic hepatitis B virus infection in children and Oriental patients. J Gastroenterol Hepatol. 1991;suppl. 1:15-17.
10. Narkewicz MR, Smith D, Silverman A, Vierling J, Sokol RJ. Clearance of chronic hepatitis B virus infection in young children after a interferon treatment. J Pediatr. 1995;127:815-818.
11. Utili R, Sagnelli E, Galanti B, et al. Prolonged treatment of children with chronic hepatitis B with recombinant α-2a-interferon: a controlled, randomized study. Am J Gastroenterol. 1991;86:327-330.
12. 2-interferon in Chinese HBsAg-carrier children. Lancet. 1987;2:877-880.
13. Leung NWY, Lai C-L, Chang T-T, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001;33:1527-1532.